InBody Co.Ltd (041830) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InBody Co.Ltd (041830) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩9.04 Billion ≈ $6.13 Million USD) by net assets (₩282.02 Billion ≈ $191.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can InBody Co.Ltd fund operations to measure how many days the company can operate on defensive assets alone.
InBody Co.Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how InBody Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InBody Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InBody Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Datang Corporation Renewable Power Co. Limited
F:DT7
|
0.046x |
|
Sk Securities
KO:001510
|
-0.069x |
|
Raymond Limited
NSE:RAYMOND
|
-0.011x |
|
Shanghai HYP-ARCH Architectural Design Consultant Co.Ltd.
SHE:301024
|
N/A |
|
Thonburi Healthcare Grp Pcl
BK:THG
|
0.024x |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
0.009x |
|
Shenzhen Hifuture Electric
SHE:002168
|
-0.359x |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
|
0.021x |
Annual Cash Flow Conversion Efficiency for InBody Co.Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of InBody Co.Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 041830 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩273.90 Billion ≈ $185.62 Million |
₩28.58 Billion ≈ $19.37 Million |
0.104x | -32.63% |
| 2023-12-31 | ₩249.83 Billion ≈ $169.31 Million |
₩38.69 Billion ≈ $26.22 Million |
0.155x | +9.58% |
| 2022-12-31 | ₩215.26 Billion ≈ $145.88 Million |
₩30.42 Billion ≈ $20.61 Million |
0.141x | -14.45% |
| 2021-12-31 | ₩183.73 Billion ≈ $124.51 Million |
₩30.35 Billion ≈ $20.57 Million |
0.165x | -13.02% |
| 2020-12-31 | ₩150.06 Billion ≈ $101.70 Million |
₩28.50 Billion ≈ $19.31 Million |
0.190x | +9.60% |
| 2019-12-31 | ₩139.69 Billion ≈ $94.67 Million |
₩24.21 Billion ≈ $16.40 Million |
0.173x | +21.74% |
| 2018-12-31 | ₩124.39 Billion ≈ $84.29 Million |
₩17.70 Billion ≈ $12.00 Million |
0.142x | -18.41% |
| 2017-12-31 | ₩106.48 Billion ≈ $72.16 Million |
₩18.58 Billion ≈ $12.59 Million |
0.174x | -11.71% |
| 2016-12-31 | ₩92.30 Billion ≈ $62.55 Million |
₩18.24 Billion ≈ $12.36 Million |
0.198x | +34.91% |
| 2015-12-31 | ₩76.32 Billion ≈ $51.72 Million |
₩11.18 Billion ≈ $7.58 Million |
0.146x | -14.89% |
| 2014-12-31 | ₩59.61 Billion ≈ $40.40 Million |
₩10.26 Billion ≈ $6.95 Million |
0.172x | +26.86% |
| 2013-12-31 | ₩51.56 Billion ≈ $34.94 Million |
₩6.99 Billion ≈ $4.74 Million |
0.136x | +43.70% |
| 2012-12-31 | ₩46.13 Billion ≈ $31.26 Million |
₩4.36 Billion ≈ $2.95 Million |
0.094x | -27.61% |
| 2011-12-31 | ₩42.14 Billion ≈ $28.56 Million |
₩5.50 Billion ≈ $3.72 Million |
0.130x | -- |
About InBody Co.Ltd
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was foun… Read more